$OMCL

Omnicell (NASDAQ: OMCL) shares fell 9.9% after the company reported Q2 results that beat expectations but issued weaker guidance. Omnicell posted Q2 revenue of $312.2 million and adjusted EPS of $0.94. For Q3, it projected revenue of about $304 million, below estimates, and next-quarter EPS guidance missed consensus.

Omnicell (NASDAQ:OMCL) reported Q2 CY2026 revenue of $312.2 million, up 7.4% year on year and 0.6% above Wall Street estimates, and non-GAAP EPS of $0.94, above consensus. For next quarter, it guided revenue to $304 million, below estimates, and guided weaker EPS. The stock fell 5.6% to $39.08.

OMNICELL, INC. (OMCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q2-26.htm EX-99.1 Document Exhibit 99.1 Contact: Omnicell, Inc. David Unger 4220 North Freeway Vice President, Investor Relations Fort Worth, TX 76137 ir@omnicell.com Omnicell Announces Second Quarter 2026 Financial Results Omnicell delivers solid second quart

Omnicell (NASDAQ: OMCL) is set to report Q2 earnings Thursday. The article notes Omnicell previously beat revenue expectations with $309.9 million revenue, up 14.9% YoY, and exceeded EPS estimates, with next-quarter EBITDA guidance above analysts’ expectations. For the upcoming quarter, analysts expect revenue up 6.8% YoY.

OMNICELL, INC. (OMCL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0000926326 0000926326 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Repo

Vanguard Capital Management has disclosed beneficial ownership of 2,274,766 shares of Omnicell (NASDAQ: OMCL) common stock, representing a 5% stake. This filing, a Schedule 13G, indicates a passive investment rather than an intent to influence the company. Vanguard holds sole dispositive power over all these shares and sole voting power over 340,249 shares.

Omnicell Inc (OMCL) shares fell 3.0% to $34.40. The company is considered undervalued by 9.3% based on its GF Value™ of $37.91, yet its GF Score™ of 79/100 suggests above-average quality. Despite the undervaluation, its current P/E ratio of 860.0x is significantly higher than its 5-year median, and insiders have sold $0.4 million worth of shares recently, with no reported buying, indicating a cautious outlook.

Omnicell, Inc. CEO Randall A. Lipps reported the vesting of 79,494 performance-based restricted stock units (RSUs) after the company met specific stock performance objectives. In connection with this vesting, 15,642 shares were withheld for tax liabilities at $34.40 per share. Following these transactions, Lipps directly holds 444,592 Common Stock shares, with additional shares held indirectly in trusts.

Omnicell (OMCL) stock is currently in a low-key consolidation phase, trading closer to its 52-week lows, as Wall Street analysts adopt a cautious stance. Despite healthy one-year returns, the market is awaiting cleaner execution of its cloud-driven, subscription-based offerings and consistent growth before pushing the stock higher. Future catalysts include recurring revenue growth, improved margins, and significant contract wins that will determine if the stock breaks out of its current holding pattern.

Squarepoint Ops LLC significantly reduced its stake in Omnicell, Inc. (NASDAQ:OMCL) by 83.3% in Q2, selling over 134,000 shares. Despite this, other institutions like Invesco and Wellington increased their holdings, with institutional investors now owning 97.70% of the company. Omnicell, a healthcare technology firm specializing in medication management, maintains a "Hold" consensus rating with a $43 target price, though one analyst upgraded its target to $50 with a "Buy" rating.